+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

COVID-19 Impact on Inovio Pharmaceuticals Inc.

1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.


This PowerPoint based report gives an important expert analysis on how COVID-19 will affect Inovio Pharmaceuticals Inc. Findings are based on the industry’s most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.

  • The coronavirus (COVID-19) company impact report analyses how the pandemic will impact Inovio Pharmaceuticals Inc. performance. Inovio’s focus is on DNA-based vaccines requiring a novel route of administration
  • Inovio’s pipeline is most active in early-stage drug development
  • INO-4800 is Inovio’s COVID-19 vaccine
  • Funding from different sources for INO-4800

Reasons to Buy
  • An overview of how Inovio Pharmaceuticals Inc. will be affected by the COVID-19 pandemic.

Table of Contents

1 Executive Summary
2 Company Overview
2.1 Key Stats
2.2 SWOT Analysis
2.3 Sales Forecast Overview
3 Regional Analysis
3.1 COVID-19 Spread vs. Location of Inovio Pharmaceuticals Inc. Trials
3.2 COVID-19 vs. Non-COVID-19 Trials
4 Reaction to COVID-19
4.1 INO-4800
4.2 Insight’s Exclusive Intel: Inovio Pharmaceuticals
4.3 Global Analyst Consensus Sales Forecast
4.4 Upcoming Events
4.5 Recent Deal Activity
5 Key Findings
6 Appendix
6.1 Methodology
6.2 About the Publisher
6.3 Contacts

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Inovio Pharmaceuticals Inc.